Xcelience Receives DEA Approval for Schedule I Drug Products

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-04-01-2015
Volume 11
Issue 4

Xcellience receives approval to handle both analytical and manufacturing of DEA Scheduled products.

 

Xcelience, a contract drug manufacturer, announced that the company has received approval from the US Drug Enforcement Agency (DEA) to develop and manufacture Schedule I controlled substances.  he license extension completes company’s approval to handle both analytical and manufacturing of DEA Scheduled products, according to a company statement. 

"Regulatory capability is a critical attribute for CDMOs," says Alex McClung, vice-president, quality at Xcelience. "This Schedule I-V license underscores our capability and extends our Suite of Services to a whole new class of therapeutic compounds."

In addition, Xcelience announced that the company is expanding its pharmaceutical development services and manufacturing capacity by adding a new facility in the Tampa area to include more pharmaceutical development labs, manufacturing, quality assurance and packaging services.  

Source: Xcellience

 

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content